Key result
Dalteparin was effective in quotidian hemodialysis, but 5 of 8 nocturnal hemodialysis patients switched back to heparin within 4 weeks due to high clotting scores.
Why the study?
Low-molecular weight heparin is used in conventional hemodialysis, but studies evaluating dalteparin in quotidian and nocturnal hemodialysis were limited.
Does dalteparin provide effective and safe anticoagulation in quotidian and nocturnal hemodialysis patients?
Observational (n=18)
Does dalteparin provide effective and safe anticoagulation in quotidian and nocturnal hemodialysis patients?
Dalteparin is effective and safe for anticoagulation in quotidian hemodialysis, but its use in nocturnal hemodialysis is limited by high clotting scores in a majority of patients.
Answers are grounded in this paper and cite their sources.
May support dalteparin in quotidian hemodialysis; leaves open its role in nocturnal hemodialysis pending trials.
INTRODUCTION: Low-molecular weight heparin, such as dalteparin, is an alternative anticoagulation method in conventional hemodialysis (HD). However, there are limited studies on its use in quotidian and nocturnal HD. We assessed the optimal dose, treatment efficacy, and patient safety of dalteparin in quotidian and nocturnal HD populations. METHODS: This study included 10 quotidian (7 in-center and 3 home) and 8 nocturnal home HD patients. Dalteparin was initiated and titrated based on clotting score in these patients. Trough anti-Xa levels were measured. The dalteparin dose, the dialyzer and HD circuit clotting scores, and bleeding episodes were recorded at 4 weeks. Patients who continued dalteparin were followed to 12 months. FINDINGS: For the 10 quotidian HD patients, the median dalteparin dose was 1875 units [1250, 2500] after 4 weeks. For nocturnal HD patients, five of the eight patients switched back to heparin due to high clotting scores while on dalteparin within 4 weeks. However, three patients continued on dalteparin at 4 weeks. After 12 months, one maintained on 5000 units and the other two maintained on 7500 units of dalteparin. All the clotting scores at month 12 were ≤2. One patient died due to an unrelated cause. For all patients who continued on dalteparin, only 9% of the HD treatments had circuit clotting score >2 after reaching stable dose. All trough anti-Xa levels were <0.1 IU/mL. There were no episodes of bleeding. Fistula compression times were not increased. DISCUSSION: This small pilot study suggests that dalteparin can be used effectively and relatively safety in quotidian HD. However, its use in nocturnal HD was only successful in a small proportion of patients. Alternative methods, including second dalteparin bolus after 4 hours of HD treatment, should be assessed for efficacy and practicality.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2019) conducted an observational in Quotidian and nocturnal hemodialysis (n=18). Dalteparin was evaluated on Dalteparin dose, dialyzer and HD circuit clotting scores, and bleeding episodes. Dalteparin was effective in quotidian hemodialysis, but 5 of 8 nocturnal hemodialysis patients switched back to heparin within 4 weeks due to high clotting scores.
Synapse has enriched 10 related papers. Consider them for comparative context: